PHE Scientific Advisor Jena's Study on Delays in Emergency Care During Marathons Picks Up Widespread Coverage
PHE Scientific Advisor Anupam Jena’s recent study published in the New England Journal of Medicine focuses on delays in emergency care and mortality in connection to major U.S. marathons. Of note, the study found that on average the time it took patients to get to the hospital during major marathons increased by 4.4 minutes, and the overall risk of heart patients dying within 30 days of hospitalization rose by 13.3 percent. The study concluded that the rise in heart patient mortality was directly connected to the additional time it took patients to get to the hospital.
Dr. Jena and his associates’ study, not surprisingly, has generated a good deal of interest with articles summarizing the findings appearing in high-profile media including The Wall Street Journal, The New York Times, The Boston Globe, and many others.
To read a summary of the study and its findings as published in The New York Times, please click here.
To read an abstract of the study as it appeared in the New England Journal of Medicine, please click here.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.